Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat with Carboplatin and Gemcitabine in Recurrent Ovarian Cancer
NCT00910000Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jun 2009
- Primary completion
- Jan 2013
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Dana-Farber Cancer Institute. Started Jun 2009; status: terminated.
02
Drugs
vorinostat
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00910000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00910000.